Therapeutic Effect of OK-432 for Lymphangioma in Children

OK-432를 사용한 소아 림프관종 치료효과

  • Jung, Sung-Eun (Department of Surgery, Seoul National University College of Medicine) ;
  • Kim, Dae-Yeon (Department of Surgery, Seoul National University College of Medicine) ;
  • Shim, In-Bo (Department of Surgery, Seoul National University College of Medicine) ;
  • Lee, Seong-Cheol (Department of Surgery, Seoul National University College of Medicine) ;
  • Park, Kwi-Won (Department of Surgery, Seoul National University College of Medicine) ;
  • Kim, Woo-Ki (Department of Surgery, Seoul National University College of Medicine)
  • 정성은 (서울대학교 의과대학 외과학교실) ;
  • 김대연 (서울대학교 의과대학 외과학교실) ;
  • 심인보 (서울대학교 의과대학 외과학교실) ;
  • 이성철 (서울대학교 의과대학 외과학교실) ;
  • 박귀원 (서울대학교 의과대학 외과학교실) ;
  • 김우기 (서울대학교 의과대학 외과학교실)
  • Published : 1998.12.30

Abstract

Lymphangioma is a congenital malformation of the lymphatic system that expands into the surrounding tissues in a manner similar to a malignant tumor. Surgical excision has been the treatment of choice, but the results are often unsatisfactory due to incomplete resection, fluid collection and recurrences. Intralesional injection of OK-432(lyophilized incubation mixture of Group A Streptococcus pyogenes of human origin) was employed in treating 24 patients with lymphangiomas between 1992 and 1997. The method was used in 21 patients as a primary therapy, and in 3 patients for unresectable or recurrent cases as a secondary treatment. The results were excellent in 8 patients (33.3%), good in 7 patients (21.8 %) and poor in 7 patients (21.8 %). The side effects were fever under $39^{\circ}C$ and local inflammation. However these symptoms subsided in a few days without serious sequelae. These results suggest that intralesional injection of OK-432 is safe and effective treatment for primary lymphangioma as well as a secondary therapy for unresectable or recurrent cases.

Keywords